Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cytek Biosciences, Inc. - Common Stock (NQ: CTKB )

5.340 -0.270 (-4.81%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Cytek Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Nasdaq Down Over 100 Points; US Pending Home Sales Increase In November
Via Benzinga
Crude Oil Gains 1%; Chicago PMI Falls In December
Via Benzinga
Exposures Fossil Fuels
Cytek Biosciences, Emergent BioSolutions, Radiopharm Theranostics And Other Big Stocks Moving Higher On Monday
Via Benzinga
Cytek Biosciences Announces $50 Million Stock Repurchase Program for 2025
From Cytek Biosciences, Inc.
Via GlobeNewswire
Preview: Cytek Biosciences's Earnings
Via Benzinga
Cytek® Biosciences Named “Overall BioTech Company of the Year” in 2024 BioTech Breakthrough Awards Program
From Cytek Biosciences, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Cytek® Biosciences Becomes First Company to Add Ability to Detect Subcellular Particles to Its Cell Sorter
World’s First Enhanced Small Particle (ESP™) Detection Sorter Enables Effective Content Isolation; Opens Door to Scientific Discoveries 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Nasdaq Surges Over 500 Points; Johnson Controls Earnings Top Views
Via Benzinga
Gold Down Over 2%; CVS Health Shares Jump After Q3 Results
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Mercury Systems Posts Strong Results, Joins ArcBest, Tesla, Kennametal, Qualys And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Cytek® Biosciences Brings Full Spectrum Profiling™ (FSP™) Technology to the Forefront at Major Clinical Conferences in the U.S. and Europe
Industry Leaders to Explore Cytek’s Advanced Cell Analysis Solutions at ICCS and ESCCA 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Achieves ISO 13485 Certification at San Diego Reagent Manufacturing Facility
Certification Emphasizes Unwavering Commitment to Quality and Is an Essential Step for U.S. Clinical Market Entry 
From Cytek Biosciences, Inc.
Via GlobeNewswire
CTKB Stock Earnings: Cytek Biosciences Misses EPS, Misses Revenue for Q2 2024
CTKB stock results show that Cytek Biosciences missed analyst estimates for earnings per share and missed on revenue for the second quarter of 2024. 
Via InvestorPlace
Cytek® Biosciences Automates Panel Design with New Intelligent Algorithm
Expanding Capabilities and Streamlining Experimental Workflows 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences Announces $50 Million Stock Repurchase Program
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to participate at the Goldman Sachs 45th Annual Global Healthcare Conference
From Cytek Biosciences, Inc.
Via GlobeNewswire
1-Laser and 2-Laser 6-Color TBNK Reagents from Cytek® Biosciences Approved for Clinical Use in China
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Adds Ability to Detect Subcellular Particles to Its Industry-Leading Cell Analysis Systems
New Enhanced Small Particle (ESP™) Detection Option for Cytek Northern Lights™ and Cytek Aurora™ Systems Expands Capabilities of Small Particle Research 
From Cytek Biosciences, Inc.
Via GlobeNewswire
CTKB Stock Earnings: Cytek Biosciences Misses EPS, Beats Revenue for Q1 2024
CTKB stock results show that Cytek Biosciences missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Cytek Biosciences Reports First Quarter 2024 Financial Results
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences to Spotlight Cell Analysis Solutions at Upcoming Conferences in the United States and Europe
Company to Conduct Educational Workshops and Tutorials at CYTO and AAI’s IMMUNOLOGY2024 
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek Biosciences to Report First Quarter 2024 Financial Results on May 8, 2024
From Cytek Biosciences, Inc.
Via GlobeNewswire
CTKB Stock Earnings: Cytek Biosciences Beats Revenue for Q4 2023
CTKB stock results show that Cytek Biosciences beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
Cytek® Biosciences Names William McCombe Chief Financial Officer
From Cytek Biosciences, Inc.
Via GlobeNewswire
Cytek® Biosciences Opens New Facility to Address Increasing Global Demand for Cutting-Edge Cell Analysis Solutions
From Cytek Biosciences, Inc.
Via GlobeNewswire
Tesla, Spirit Airlines, New York Community Bancorp And Other Big Stocks Moving Lower On Monday
U.S. stocks were lower, with the Dow Jones index falling around 80 points on Monday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results. 
Via Benzinga
Cytek Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Outlook
From Cytek Biosciences, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.